These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29868159)

  • 1. HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz.
    Drury A; Gleadow-Ware S; Gilfillan S; Ahrens J
    Malawi Med J; 2018 Mar; 30(1):40-45. PubMed ID: 29868159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom.
    Law JKC; Butler LT; Hamill MM
    AIDS Res Hum Retroviruses; 2020 Jun; 36(6):459-466. PubMed ID: 31931589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
    Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E
    BMC Infect Dis; 2013 Jun; 13():261. PubMed ID: 23734829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of the psychiatric side-effects of efavirenz.
    Kenedi CA; Goforth HW
    AIDS Behav; 2011 Nov; 15(8):1803-18. PubMed ID: 21484283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No Evidence of an Association Between Efavirenz Exposure and Suicidality Among HIV Patients Initiating Antiretroviral Therapy in a Retrospective Cohort Study of Real World Data.
    Nkhoma ET; Coumbis J; Farr AM; Johnston SS; Chu BC; Rosenblatt LC; Seekins D; Villasis-Keever A
    Medicine (Baltimore); 2016 Jan; 95(3):e2480. PubMed ID: 26817882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.
    Gaida R; Truter I; Grobler C; Kotze T; Godman B
    Expert Rev Anti Infect Ther; 2016; 14(4):377-88. PubMed ID: 26900637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial.
    Dabaghzadeh F; Ghaeli P; Khalili H; Alimadadi A; Jafari S; Akhondzadeh S; Khazaeipour Z
    AIDS Patient Care STDS; 2013 Mar; 27(3):146-54. PubMed ID: 23442031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
    Muñoz-Moreno JA; Fumaz CR; Ferrer MJ; González-García M; Moltó J; Negredo E; Clotet B
    AIDS Rev; 2009; 11(2):103-9. PubMed ID: 19529750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study.
    Chang JL; Tsai AC; Musinguzi N; Haberer JE; Boum Y; Muzoora C; Bwana M; Martin JN; Hunt PW; Bangsberg DR; Siedner MJ
    Ann Intern Med; 2018 Aug; 169(3):146-155. PubMed ID: 29946683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
    Mills AM; Antinori A; Clotet B; Fourie J; Herrera G; Hicks C; Madruga JV; Vanveggel S; Stevens M; Boven K;
    HIV Med; 2013 Aug; 14(7):391-400. PubMed ID: 23298380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz-induced gynecomastia in a prepubertal girl with human immunodeficiency virus infection: a case report.
    van Ramshorst MS; Kekana M; Struthers HE; McIntyre JA; Peters RP
    BMC Pediatr; 2013 Aug; 13():120. PubMed ID: 23941256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of Efavirenz in Paediatric Patients: Why do Children Switch?
    Wynberg E; Williams E; Tudor-Williams G; Lyall H; Foster C
    Clin Drug Investig; 2018 Mar; 38(3):231-238. PubMed ID: 29181714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
    Chang JL; Lee SA; Tsai AC; Musinguzi N; Muzoora C; Bwana B; Boum Y; Haberer JE; Hunt PW; Martin J; Bangsberg DR; Kroetz DL; Siedner MJ
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):982-992. PubMed ID: 29973058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neurospychiatric symptoms in HIV infected patients and the role of efavirenz].
    Bary M; David F; Gasnault J; Kerneis H; Linard F; Longuet P; Pelissolo A; Ravaux I
    Med Mal Infect; 2004 Oct; 34(10):435-49. PubMed ID: 15747468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
    João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
    Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015.
    Bengtson AM; Pence BW; Eaton EF; Edwards JK; Eron JJ; Mathews WC; Mollan K; Moore RD; O'Cleirigh C; Geng E; Mugavero MJ
    Antivir Ther; 2018; 23(4):363-372. PubMed ID: 29424697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
    Mugusi S; Ngaimisi E; Janabi M; Mugusi F; Minzi O; Aris E; Bakari M; Bertilsson L; Burhenne J; Sandstrom E; Aklillu E
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1405-1415. PubMed ID: 30003275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
    Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
    Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
    Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
    Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute psychosis as a side effect of efavirenz therapy with metabolic anomalies: an important differential diagnosis of HIV-associated psychoses].
    Hinsch MC; Reichelt D; Husstedt IW
    Nervenarzt; 2014 Oct; 85(10):1304-8. PubMed ID: 25200885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.